Kelzyn

Dienogest/Ethinylestradiol, the active ingredient in Kelzyn, is a combined oral contraceptive presented as a tablet for oral use. It works by inhibiting ovulation and altering cervical mucus and endometrial lining, thereby preventing fertilisation and implantation in women of reproductive age seeking reliable contraception.

GNH USA supplies Kelzyn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality and regulatory‑aligned sourcing for global contraceptive needs. Our distribution network ensures timely delivery and compliance with local import regulations.

Kelzyn, a combined oral contraceptive, is indicated for hormonal contraception in women.

Prevention of pregnancy: provides reliable contraceptive protection by suppressing ovulation and altering cervical mucus. Hormonal contraception: maintains regular menstrual cycles while preventing fertilisation. Family planning: offers a reversible, user‑controlled method for women seeking to avoid unintended pregnancy.

Kelzyn may cause a range of adverse reactions. Most are mild and transient, but serious events can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional throbbing or tension‑type pain. - Breakthrough bleeding: spotting between periods. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to the lungs. - Stroke or myocardial infarction: severe cardiovascular events. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: abnormal liver enzyme levels. - Vision changes: rare ocular disturbances.

Before prescribing Kelzyn, clinicians should assess individual risk factors and advise patients accordingly.

Contraindicated in pregnancy: product is classified as Category X and must not be used by pregnant women. Avoid in smokers over 35: increased risk of cardiovascular events. Screen for thromboembolic risk: assess history of clotting disorders before prescribing. Monitor blood pressure: oral contraceptives may elevate BP. Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Kelzyn can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine): reduced contraceptive efficacy. - Rifampicin and other strong inducers: may decrease hormone levels. - HIV protease inhibitors: potential pharmacokinetic interactions.

Moderate Interactions (Monitor Closely): - St. John’s wort: may lower hormone concentrations. - Antifungal azoles (e.g., ketoconazole): may increase hormone exposure. - Selective serotonin reuptake inhibitors: possible mood‑related effects.